Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Accured Expenses (2016 - 2025)

Kiora Pharmaceuticals' Change in Accured Expenses history spans 11 years, with the latest figure at $233904.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 92.1% year-over-year to $233904.0; the TTM value through Dec 2025 reached -$2.3 million, down 171.25%, while the annual FY2025 figure was -$2.3 million, 171.25% down from the prior year.
  • Change in Accured Expenses reached $233904.0 in Q4 2025 per KPRX's latest filing, up from -$412015.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.0 million in Q4 2024 to a low of -$1.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $60414.2, with a median of $72375.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: surged 3081.99% in 2024, then crashed 1078.47% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$59168.0 in 2021, then soared by 949.77% to $502792.0 in 2022, then crashed by 119.75% to -$99315.0 in 2023, then soared by 3081.99% to $3.0 million in 2024, then crashed by 92.1% to $233904.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Change in Accured Expenses are $233904.0 (Q4 2025), -$412015.0 (Q3 2025), and -$1.1 million (Q2 2025).